咪唑并[1,5 - a ]喹喔啉-4-酮环系的新构建策略及其在高效新型Lck抑制剂BMS-238497的高效合成中的应用
摘要:
为构建咪唑并[1,5 - a ]喹喔啉-4-一环系统开发了一种新的有效策略。新方法涉及将邻硝基苯胺与乙醛酸酯在甲醇中缩合,然后用甲苯磺酰基甲基异氰化物(TosMIC)试剂处理所得的α-(邻硝基苯胺基)-α-甲氧基乙酸酯,得到1-(邻硝基苯基)咪唑-5 -羧酸盐。硝基咪唑羧酸盐的还原环化以三个步骤提供咪唑并[1,5 - a ]喹喔啉-4-酮,总产率为60%。该新方法已成功应用于合成新型有效的Lck抑制剂BMS-238497。
咪唑并[1,5 - a ]喹喔啉-4-酮环系的新构建策略及其在高效新型Lck抑制剂BMS-238497的高效合成中的应用
摘要:
为构建咪唑并[1,5 - a ]喹喔啉-4-一环系统开发了一种新的有效策略。新方法涉及将邻硝基苯胺与乙醛酸酯在甲醇中缩合,然后用甲苯磺酰基甲基异氰化物(TosMIC)试剂处理所得的α-(邻硝基苯胺基)-α-甲氧基乙酸酯,得到1-(邻硝基苯基)咪唑-5 -羧酸盐。硝基咪唑羧酸盐的还原环化以三个步骤提供咪唑并[1,5 - a ]喹喔啉-4-酮,总产率为60%。该新方法已成功应用于合成新型有效的Lck抑制剂BMS-238497。
Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
申请人:——
公开号:US20040180898A1
公开(公告)日:2004-09-16
Novel processes for the preparation of imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines are described.
A new facile method for the synthesis of 1-arylimidazole-5-carboxylates
作者:Bang-Chi Chen、Mark S Bednarz、Rulin Zhao、Joseph E Sundeen、Ping Chen、Zhongqi Shen、Amanda P Skoumbourdis、Joel C Barrish
DOI:10.1016/s0040-4039(00)00910-2
日期:2000.7
A new facile method for the preparation of 1-arylimidazole-5-carboxylates was developed. The new method involved reaction of anilines and ethyl glyoxylate in methanol to give alpha-anilino-alpha-methoxyacetates followed by cyclization with TosMIC, affording 1-arylimidazole-5-carboxylates in two steps in 40-94% overall yields. (C) 2000 Elsevier Science Ltd. All rights reserved.
[EN] PROCESSES FOR PREPARING IMIDAZOQUINOXALINONES, HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINONES, IMIDAZOUINOXALINES AND HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINES<br/>[FR] PROCEDES POUR PREPARER DES IMIDAZOQUINOXALINONES, DES IMIDAZOPYRAZINONES A SUBSTITUTION HETEROCYCLIQUE, DES IMIDAZOQUINOXALINES ET DES IMIDAZOPYRAZINES A SUBSTITUTION HETEROCYCLIQUE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004078714A2
公开(公告)日:2004-09-16
Novel processes for the preparation of imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines are described.